Amylyx prices upsized 14,090,000-share follow-on at $35.5/share for $500.2 million gross proceeds

• Amylyx priced an upsized underwritten public offering of 14,090,000 common shares at USD 35.5 per share.
• Gross proceeds expected at about USD 500.2 million before fees, excluding any underwriters’ option exercise.
• Underwriters hold a 30-day option to buy up to 2,113,500 additional shares.
• Net proceeds earmarked for avexitide pre-commercial work, R&D, working capital, general corporate purposes.
• Closing expected on or about Aug. 21, 2026, subject to customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260819148986) on August 20, 2026, and is solely responsible for the information contained therein.